Abeprazan

Summary

Abeprazan (CHEMBL4594445) is a phase-3 clinical-stage small molecule (ATC A02BC10); indicated across 4 conditions including gastroesophageal reflux disease and peptic ulcer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A02BC10
• Indications: 4 conditions
• Clinical trials: 24
• Chemistry: 410.4 Da · C19H17F3N2O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594445
Name	Abeprazan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	122662112
ATC	A02BC10
Molecular formula	C19H17F3N2O3S
Molecular weight	410.4
InChIKey	OUNXGNDVWVPCOL-UHFFFAOYSA-N

SMILES: CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F

IUPAC name: 1-[5-(2,4-difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine

Also known as: Abeprazan, DWP-14012, Dwp14012, DWP14012, Fexuprazan, ABEPRAZAN

Parent form; salt/anhydrous children: CHEMBL6068511

Patent coverage: 52 distinct patent families (120 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroesophageal reflux disease	3	MONDO:0007186	EFO:0003948
peptic ulcer disease	3	MONDO:0004247	HP:0004398
chronic gastritis	3	MONDO:0005001	EFO:0000337
peptic esophagitis	3	MONDO:0006896	EFO:1001095

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
PHASE1	10
PHASE3	7
Not specified	5
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07533266	PHASE4	NOT_YET_RECRUITING	Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer
NCT03736369	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)
NCT04341428	PHASE3	UNKNOWN	Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis
NCT04784910	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
NCT05813561	PHASE3	COMPLETED	The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
NCT06121830	PHASE3	UNKNOWN	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
NCT06751121	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
NCT07326904	PHASE3	COMPLETED	Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease
NCT03184324	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)
NCT06437951	PHASE1	NOT_YET_RECRUITING	to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection
NCT02757144	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers
NCT03574415	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean
NCT04328766	PHASE1	COMPLETED	Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
NCT04490434	PHASE1	UNKNOWN	Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs
NCT04827472	PHASE1	UNKNOWN	Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers
NCT05304845	PHASE1	COMPLETED	Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects
NCT05574374	PHASE1	COMPLETED	Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
NCT05812404	PHASE1	UNKNOWN	Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects
NCT06508645	PHASE1	COMPLETED	Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers
NCT07479056	Not specified	RECRUITING	Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
NCT07497893	Not specified	NOT_YET_RECRUITING	FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
NCT04613895	Not specified	UNKNOWN	Treatment Effect According to Timing of Administration of DWP14012 40 mg
NCT04888819	Not specified	UNKNOWN	Treatment Effect According to Timing of Administration of DWP14012 40 mg
NCT05614752	Not specified	COMPLETED	Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).